Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer''s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Latest shares articles
Trading the Nasdaq 100 as Tariffs Take Effect
Not far off recovering from last Thursday’s losses buoyed by big gains from a few of Big Tech, and in sentiment still a story of majority buy bias.
06:35, 7 August 2025
Capital.com donates €50,000 to the Cyprus Red Cross Society to support wildfire relief efforts
Capital.com donates €50,000 to the Cyprus Red Cross Society to aid families affected by wildfires, reinforcing its commitment to community support.
09:49, 5 August 2025
Trading the Dow 30 after the disappointing Non-Farm Payrolls
Technical overview shifts in the key index following the pullback late last week made worse by a deteriorating labor market, while CoT speculators shift to net sell for the first time in months.
07:55, 4 August 2025
Forex CFDs: Understanding currency forwards vs spot markets
Spot or forward? These two forex markets behave differently, and now you can trade both with us as forex CFDs. Here’s how they work, and what sets them apart.
14:48, 31 July 2025
Ratings and Reviews
Ratings and Reviews
